Implementation Strategies for Monitoring Adherence in Real Time

Back to Search
Print
Bookmark Trial

NCT04347161

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
See other locations
Contact
215-662-9147
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

215-662-9147

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Lung Cancer, Medication Adherence, Symptoms and Signs
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Adult patient with advanced NSCLC who is receiving care at a recruiting site and is taking an FDA-approved oral targeted therapies including but not limited to: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.

- Patient possession of a mobile device that can send/receive SMS texts

- Ability to respond to questions and engage with text messages in English

- Ability to provide informed consent to participate in the study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Inability to respond to questions and engage with text messages in English


- Inability or unwillingness to provide informed consent to participate in the study


- Inability to engage with SMS text-messaging platform


- Concurrent enrollment in another clinical trial involving oral targeted therapies or
adherence to care

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Lung Cancer, Medication Adherence, Symptoms and SignsImplementation Strategies for Monitoring Adherence in Real Time
NCT04347161
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Implementation Strategies for Monitoring Adherence in Real Time
Official Title  ICMJE Implementation Strategies for Monitoring Adherence in Real Time
Brief Summary The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Detailed Description Drawing from insights in behavioral economics and implementation science, the goal of our project is to identify effective strategies for improving lung cancer outcomes by helping patients to better manage symptoms and adhere to oral therapies. Given the rapid increase in FDA-approved targeted therapies, the need for such strategies will continue to grow. Our central hypothesis is that conversational agent will improve adherence to oral therapies by targeting patient-level determinants of behavior change. The specific aims are to: 1) Test the effects of a patient-directed intervention (conversational agent) to improve adherence to oral targeted therapies in patients with non-small cell lung cancer.; and 2) Use mixed-methods approaches with clinicians and patients to explore multilevel factors shaping the acceptability, effectiveness, and future implementation of intervention into routine cancer care. Primary trial outcomes (adherence and persistence) will be measured using microelectronic monitoring system (MEMS) caps. Secondary outcomes will be assessed using longitudinal surveys and medical record data.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients with lung cancer receiving oral targeted therapies at recruitment sites will be randomized (1:1 stratified by drug class and prescription status) to receive intervention or usual care.
Masking: Single (Outcomes Assessor)
Masking Description:
Due to the nature of the intervention, participants and their care providers (including investigators) will not be blinded. The primary analyst and outcomes assessor will be blinded. Blinding may be broken in an emergency.
Primary Purpose: Supportive Care
Condition  ICMJE
  • Lung Cancer
  • Medication Adherence
  • Symptoms and Signs
Intervention  ICMJE
  • Device: Conversational Agent/Chatbot
    Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
  • Other: Usual Care
    Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Study Arms  ICMJE
  • Experimental: Intervention Arm
    Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
    Intervention: Device: Conversational Agent/Chatbot
  • Active Comparator: Control Arm
    Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
    Intervention: Other: Usual Care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 23, 2021)		170
Original Estimated Enrollment  ICMJE
 (submitted: April 10, 2020)		144
Estimated Study Completion Date  ICMJE December 31, 2021
Estimated Primary Completion Date December 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult patient with advanced NSCLC who is receiving care at a recruiting site and is taking an FDA-approved oral targeted therapies including but not limited to: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
  • Patient possession of a mobile device that can send/receive SMS texts
  • Ability to respond to questions and engage with text messages in English
  • Ability to provide informed consent to participate in the study

Exclusion Criteria:

  • Inability to respond to questions and engage with text messages in English
  • Inability or unwillingness to provide informed consent to participate in the study
  • Inability to engage with SMS text-messaging platform
  • Concurrent enrollment in another clinical trial involving oral targeted therapies or adherence to care
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Katharine A Rendle, PhD,MSW,MPH215-662-9147[email protected]
Contact: Jocelyn V Wainwright, MS215-662-9128[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04347161
Other Study ID Numbers  ICMJE 834713
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party University of Pennsylvania
Study Sponsor  ICMJE University of Pennsylvania
Collaborators  ICMJE
  • Lung Cancer Research Foundation
  • Pfizer
Investigators  ICMJE
Principal Investigator:Katharine A Rendle, PhD,MSW,MPHUniversity of Pennsylvania
Principal Investigator:Samuel U Takvorian, MD, MSHPUniversity of Pennsylvania
PRS Account University of Pennsylvania
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP